Kevin Noonan
Articles by Kevin Noonan
| 4 min read
Decision provides a consistent standard based on structure even though resulting scope may prove insufficient for justifying costs of commercialization
| 5 min read
Trying to overcome misinterpretations of the Supreme Court's decisions on patent eligibility by district courts and the Federal Circuit
| 5 min read
An ounce of prevention was certainly worth the pound of its eventual cure when it comes to assigning inventions
| 4 min read
The arguments over "first to invent" and ownership of CRISPR tech continue
| 4 min read
GlaxoSmithKline LLC v. Teva Pharmaceuticals (Fed. Cir. 2020) addresses what quantum of culpable conduct is required
| 5 min read
The same evidence that supports non-obviousness for patentability can also restrict the scope of what has been described
| 5 min read
Once again this year, the report highlights compulsory licensing as a particular concern with regard to pharmaceuticals and medical devices
| 4 min read
According to Kevin Noonan, writing about a recent court ruling, the answer is a resounding..."Maybe"
| 4 min read
Patent Docs' Kevin Noonan talks about the potential peril of using a layperson to provide expert testimony
| 4 min read
The Federal Circuit continuse to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinion
| 3 min read
Kevin Noonan discusses a case in which the University of Texas sued Boston Scientific for patent infringement related to implantable drug-releasing biodegradable fibers
| 3 min read
Kevin Noonan discusses recent developments around researchers vying for ownership of aspects of the gene-editing technology directed to eukaryotic cells
| 4 min read
Kevin Noonan, a partner with the law firm McDonnell Boehnen Hulbert & Berghoff LLP and founding author of the Patent Docs weblog, recaps the highlights of the latest annual BIO meeting
| 4 min read
Kevin Noonan discusses the Biologic Patent Transparency Act and how he thinks the U.S. Congress might be picking the wrong target (patents) as a way to decrease drug prices and increase transparency
| 4 min read
Federal Circuit panel disputes question in Barry v. Medtronic
Page 1 of 4 - 51 Total Items
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Driving gene therapy with nonviral vectors
Learn why nonviral vectors are on the rise in gene therapy development.
Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis
Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Advancing immuno-oncology research with cellular assays
Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
